NephroGenex (NRXGQ) Stock Price, News & Analysis

Company Overview

NephroGenex, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for kidney and vascular disorders. The company’s R&D efforts center on in-licensed and proprietary compounds designed to address the progressive nature of chronic kidney disease, diabetic nephropathy and acute kidney injury. By targeting anti-fibrotic and anti-inflammatory pathways, NephroGenex aims to slow disease progression and improve patient quality of life.

The company’s pipeline comprises early- and mid-stage product candidates that have advanced through preclinical evaluation, with select programs entering clinical proof-of-concept studies. NephroGenex pursues strategic collaborations and licensing agreements to enhance its research capabilities and expedite development timelines. These partnerships enable access to complementary expertise in medicinal chemistry, translational research and regulatory strategy.

Headquartered in the United States, NephroGenex trades on the OTC Markets under the symbol NRXGQ. The company is led by an experienced management team with backgrounds in pharmaceutical development, clinical operations and commercialization. NephroGenex remains committed to translating its scientific insights into treatments that address significant unmet needs in kidney and vascular health.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 2,000 shs
• Average Volume: 26,223 shs
• Market Capitalization: $36 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Manufacturing
• Industry: Electronic Computer Manufacturing
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:NRXGQ
• Previous Symbol: NASDAQ:NRX
• CIK: 1338095
• Web: www.nephrogenex.com
• Phone: +1-609-5538887
• Fax: N/A
• Employees: 1,700
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 12,950,000
• Free Float: N/A
• Market Cap: $36 thousand
• Optionable: Not Optionable
• Beta: N/A